-
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
NCT07222618 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: San Francisco
-
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
NCT06587828 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Orange, Sherman Oaks
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· California: San Francisco
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Fresno, Newport Beach, Orange, West Hollywood
-
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Newport Beach, Palo Alto
-
A Study of AZD0120 in Autoimmune Diseases
NCT07295847 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Stanford
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06138132 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Palo Alto
-
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· California: West Hollywood
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· California: Fullerton, Torrance, West Hollywood
-
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: La Jolla
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Fullerton, West Hollywood
-
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Stanford
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Palo Alto
-
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: La Jolla
-
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
NCT05359653 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· California: San Francisco
-
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
NCT02521311 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· California: San Francisco
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· California: Palo Alto
-
Care in Multiple Sclerosis (MS)
NCT07011914 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: San Francisco
-
Central Vein Sign in Multiple Sclerosis Extension Study
NCT07424027 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Los Angeles
-
ECoG BMI for Motor and Speech Control
NCT03698149 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years and older ·
Sex: All (male and female)
· California: San Francisco
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· California: Irvine
-
Entire-body PET Scans for Multiple Sclerosis
NCT04390009 ·
Phase: Early Phase 1 ·
Ages: 25 Years to 55 Years ·
Sex: All (male and female)
· California: Ladera Ranch
-
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
NCT07510607 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: San Francisco
-
Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· California: La Jolla
-
MS-ResearchBiomarkerS
NCT05204459 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Los Angeles
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· California: West Hollywood
-
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· California: Redwood City
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: La Jolla, San Francisco
-
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· California: Los Angeles, San Francisco, San Pablo
-
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
NCT04933552 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: Female
· California: La Jolla
-
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
NCT06940323 ·
Phase: Not specified ·
Ages: 18 Years to 64 Years ·
Sex: Female
· California: San Francisco
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: San Diego, Santa Rosa
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: San Francisco, Stanford
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· California: Los Angeles, Palo Alto
-
Study of COYA 302 for the Treatment of ALS
NCT07161999 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Los Angeles, San Francisco
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Orange
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· California: Loma Linda, Sacramento
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· California: Loma Linda, Los Angeles, Oakland
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Palo Alto, Sacramento
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 60 Years ·
Sex: All (male and female)
· California: Irvine